$MSTX at breakout $0.4579 AMEX Bats ascending tri
Post# of 63700
Posted On: 06/22/2016 10:51:47 AM
$MSTX at breakout $0.4579
AMEX Bats ascending triangle
Website
Shares Outstanding: 192.84M
Float: 173.41M
% Held by Insiders: 0.26%
% Held by Institutions: 22.90%
Shares Short (as of May 31, 2016): 7.25M
Short Ratio (as of May 31, 2016): 3.59
Short % of Float (as of May 31, 2016): 3.77%
Shares Short (prior month): 6.00M
Headlines
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases with significant unmet needs. The companys lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease, and heart failure. It also develops AIR001, a sodium nitrite solution for intermittent inhalation via nebulizer, as well as for the treatment of heart failure with preserved ejection fraction. The company was formerly known as ADVENTRX Pharmaceuticals, Inc. and changed its name to Mast Therapeutics, Inc. in March 2013. Mast Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
AMEX Bats ascending triangle
Website
Shares Outstanding: 192.84M
Float: 173.41M
% Held by Insiders: 0.26%
% Held by Institutions: 22.90%
Shares Short (as of May 31, 2016): 7.25M
Short Ratio (as of May 31, 2016): 3.59
Short % of Float (as of May 31, 2016): 3.77%
Shares Short (prior month): 6.00M
Headlines
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases with significant unmet needs. The companys lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease, and heart failure. It also develops AIR001, a sodium nitrite solution for intermittent inhalation via nebulizer, as well as for the treatment of heart failure with preserved ejection fraction. The company was formerly known as ADVENTRX Pharmaceuticals, Inc. and changed its name to Mast Therapeutics, Inc. in March 2013. Mast Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
(0)
(0)Scroll down for more posts ▼